210 related articles for article (PubMed ID: 32339767)
1. The minimally effective dose of bone morphogenetic protein in posterior lumbar interbody fusion: a systematic review and meta-analysis.
Lytle EJ; Lawless MH; Paik G; Tong D; Soo TM
Spine J; 2020 Aug; 20(8):1286-1304. PubMed ID: 32339767
[TBL] [Abstract][Full Text] [Related]
2. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine.
Chrastil J; Low JB; Whang PG; Patel AA
Spine (Phila Pa 1976); 2013 Jul; 38(16):E1020-7. PubMed ID: 23629484
[TBL] [Abstract][Full Text] [Related]
3. Exploratory meta-analysis on dose-related efficacy and morbidity of bone morphogenetic protein in spinal arthrodesis surgery.
Hofstetter CP; Hofer AS; Levi AD
J Neurosurg Spine; 2016 Mar; 24(3):457-75. PubMed ID: 26613283
[TBL] [Abstract][Full Text] [Related]
4. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
[TBL] [Abstract][Full Text] [Related]
5. Fusion rate of Escherichia coli-derived recombinant human bone morphogenetic protein-2 compared with local bone autograft in posterior lumbar interbody fusion for degenerative lumbar disorders.
Park S; Jeong YH; Ha BJ; Yoo BS; Kim SH; Lee CK; Yi S; Ha Y; Kim KN; Shin DA
Spine J; 2023 Dec; 23(12):1877-1885. PubMed ID: 37516282
[TBL] [Abstract][Full Text] [Related]
6. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
7. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
8. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
9. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
Wong DA; Kumar A; Jatana S; Ghiselli G; Wong K
Spine J; 2008; 8(6):1011-8. PubMed ID: 18037352
[TBL] [Abstract][Full Text] [Related]
10. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
11. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion.
Helgeson MD; Lehman RA; Patzkowski JC; Dmitriev AE; Rosner MK; Mack AW
Spine J; 2011 Jun; 11(6):507-10. PubMed ID: 21729801
[TBL] [Abstract][Full Text] [Related]
12. Transforaminal lumbar interbody fusion (TLIF) versus posterior lumbar interbody fusion (PLIF) in lumbar spondylolisthesis: a systematic review and meta-analysis.
de Kunder SL; van Kuijk SMJ; Rijkers K; Caelers IJMH; van Hemert WLW; de Bie RA; van Santbrink H
Spine J; 2017 Nov; 17(11):1712-1721. PubMed ID: 28647584
[TBL] [Abstract][Full Text] [Related]
13. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative and perioperative complications in minimally invasive transforaminal lumbar interbody fusion: a review of 513 patients.
Wong AP; Smith ZA; Nixon AT; Lawton CD; Dahdaleh NS; Wong RH; Auffinger B; Lam S; Song JK; Liu JC; Koski TR; Fessler RG
J Neurosurg Spine; 2015 May; 22(5):487-95. PubMed ID: 25700243
[TBL] [Abstract][Full Text] [Related]
15. Complications of spinal fusion with utilization of bone morphogenetic protein: a systematic review of the literature.
Singh K; Ahmadinia K; Park DK; Nandyala SV; Marquez-Lara A; Patel AA; Fineberg SJ
Spine (Phila Pa 1976); 2014 Jan; 39(1):91-101. PubMed ID: 24026158
[TBL] [Abstract][Full Text] [Related]
16. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis.
Joseph V; Rampersaud YR
Spine (Phila Pa 1976); 2007 Dec; 32(25):2885-90. PubMed ID: 18246013
[TBL] [Abstract][Full Text] [Related]
17. Time Course Observation of Outcomes between Minimally Invasive Transforaminal Lumbar Interbody Fusion and Posterior Lumbar Interbody Fusion.
Lin GX; Park CK; Hur JW; Kim JS
Neurol Med Chir (Tokyo); 2019 Jun; 59(6):222-230. PubMed ID: 31068542
[TBL] [Abstract][Full Text] [Related]
18. Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
De Stefano FA; Elarjani T; Burks JD; Burks SS; Levi AD
World Neurosurg; 2021 Dec; 156():e64-e71. PubMed ID: 34530148
[TBL] [Abstract][Full Text] [Related]
19. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases.
Lewandrowski KU; Nanson C; Calderon R
Spine J; 2007; 7(5):609-14. PubMed ID: 17526434
[TBL] [Abstract][Full Text] [Related]
20. Perioperative outcomes and adverse events of minimally invasive versus open posterior lumbar fusion: meta-analysis and systematic review.
Goldstein CL; Macwan K; Sundararajan K; Rampersaud YR
J Neurosurg Spine; 2016 Mar; 24(3):416-27. PubMed ID: 26565767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
